勃起功能障碍药物治疗的研究现状  

Research status of erectile dysfunction pharmacotherapy

作　　者：龚知城 左翼[1] 钟义洋 赵善超[1] GONG Zhicheng1, ZUO Yi1, ZHONG Yiyang1,2, ZHAO Shanchao1(1Department of Urology, Nan fang Hospital/The First School of Clinical Medicine of Southern Medical University, Guangzhou 510515, China; 2Department of Urology, The Sixth People＇s Hospital of Guangzhou Panyu, Guangzhou 511422,Chin)

机构地区：[1]南方医科大学南方医院泌尿外科,广东广州510515 [2]广州番禺第六人民医院泌尿外科,广东广州511422

出　　处：《分子影像学杂志》2018年第2期201-206,共6页Journal of Molecular Imaging

摘　　要：虽然口服磷酸二酯酶-5抑制剂、雄激素治疗是目前治疗勃起功能障碍的常见治疗方式,但是由于勃起功能障碍具有多种致病机制,部分患者对这些药物反应不佳。许多研究人员试图寻找新的治疗策略。靶向药物治疗针对中枢和外周途径。中枢作用的包括黑皮质素受体激动剂、多巴胺能激动剂、克拉维酸(紫杉醇)。外周作用的包括可溶性鸟苷酸环化酶活化剂和Rho激酶抑制剂。蛋白质疗法和基因疗法通过恢复或再生海绵体血管内皮细胞、海绵体神经或抑制继发于神经血管功能障碍的组织纤维化,使受损的阴茎勃起组织再生。文章回顾磷酸二酯酶-5抑制剂治疗、雄激素治疗,介绍临床或临床前研究中勃起功能障碍的药物治疗策略,其研究结果为将来的临床应用打下了坚实的基础。Although oral phosphodiesterase-5（PDE5） inhibitors and androgen therapy are common treatments for erectile dysfunction（ED）, some patients respond poorly to these drugs because of ED＇s multiple pathogenic mechanisms. Many researchers have tried to find new treatment strategies, and targeted therapy alternatives include the central and peripheral pathways. Centrally acting agents include melanocortin receptor agonists, dopaminergic agonists and clavulanic acid（paclitaxel）, while peripherally acting agents include soluble guanylate cyclase activators and Rho kinase inhibitor.Proteotherapy and gene therapy regenerate damaged erectile tissues by rejuvenating or regenerating cavernous endothelial cells and cavernous nerves or by inhibiting the fibrosis of tissues secondary to neurovascular dysfunction. This article reviews the PDE5 inhibitor therapy and androgen therapy, and introduces clinical and preclinical ED pharmacotherapy strategies, the results of which have laid a solid foundation for future clinical applications.

关 键 词：勃起功能障碍 药物治疗 临床前研究 

分 类 号：R698[医药卫生—泌尿科学]